Bispecific Antibodies Market By Type (Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597), By Application (BsMAb for Cancer Diagnostic, BsMAb for Diagnosis of Bacterial & Infectious Diseases, BsAbs Blocking Signaling Pathways, BsAbs Targeting Tumor Angiogenesis, and Others), By End-User (Hospitals, Clinics and Research Centers) and By Region - Market Trends, Analysis, and Forecast till 2030.

Bispecific Antibodies Market accounted for USD 484.9 Million in 2019 and is estimated to be USD 915.4 Million by 2029 and is anticipated to register a CAGR of 6.6%.

Bispecific antibodies are artificial proteins where two or more antigen recognizing elements are combined together to form a single construct. Bispecific antibodies have the ability to bind with two or more targets at a time. The structure of the antibodies include quadromas, chemical heteroconjugates, bispecific antibodies with special heterodimerization domains and biospecific antibodies of minimal size. The advantages include dual targeting of disease mediators and delivering payloads to targeted site. FDA approved two bispecific antibody products Catumaxomab and blinatumomab. Many key players are conducting research on symmetric bispecific antibody. BEAT, duobody and crossmab are some of the asymmetric bispecific antibodies which are targeted by some major key players such as Eli Lilly and Company, Genmab A/S.

Increasing cancer patient and advancement in technologies for the treatment

The increase in mortality and morbidity rates among patients is one of the driver of this market. For instance, according to the WHO, there are approximately 14 million cancer cases every year and the rates are constantly increasing. Almost 1.9 million new cancer cases are expected to be diagnosed in 2021.

Increasing investments to harness the potential of highly effective bispecific antibody drug therapy

Various pharmaceutical companies are involved in the development and manufacture of bispecific antibodies. For instance, MedImmune, LLC and Abpro, collaborated in December 2016 to develop novel bispecific antibody, Ang2-VEGF, which targets angiopoietin-2 and vascular endothelial growth factor. Government funding is projected to further encourage research and development in the field of bispecific antibodies.

However, technical and clinical-related challenges might hamper the growth of the global market to a certain extent.

The Global Bispecific Antibodies Market is segmented based on type, application, end-user and region.

On the basis of type, the Global Bispecific Antibodies Market is segmented into Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597. On the basis of application, the target market is segmented into BsMAb for Cancer Diagnostic, BsMAb for Diagnosis of Bacterial & Infectious Diseases, BsAbs Blocking Signaling Pathways, BsAbs Targeting Tumor Angiogenesis, and Others. On the basis of end-user, the target market is segmented into hospitals, clinics and research centers.

Regional Insights:

On region the Global Bispecific Antibodies Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are the dominating regions having largest market share of bispecific antibodies due to well-developed healthcare infrastructure, high cancer prevalence and presence of major key players in the regions. In addition, favorable initiatives taken by federal government also contribute for market growth of North American and European regions. Similarly, Asia Pacific is untapped market due to improper healthcare facilities in some Asian countries.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2030. For the purpose of this study, has segmented the Global Bispecific Antibodies Market report based on product, site of collection, application, and region. 

Global Bispecific Antibodies Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
    • Rest of Middle East & Africa

The key players operating in the Global Bispecific Antibodies Market include Aspen Holdings, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, GlaxoSmithKline plc., Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Pfizer, Inc, Portola Pharmaceuticals, Inc., Sanofi S.A. and Others.

• Sanofi S.A.
• Aspen Holdings
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company
• Limited
• GlaxoSmithKline plc.
• Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
• Pfizer, Inc
• Portola Pharmaceuticals, Inc.
• Others